Cross-Protective Efficacy of a ProphylacticLeishmania donovaniDNA Vaccine against Visceral and Cutaneous Murine Leishmaniasis
- 1 February 2005
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (2) , 812-819
Abstract
The fucose-mannose ligand (FML) complex ofLeishmania donovaniis a promising vaccine candidate against murine and canine visceral leishmaniasis, and its main component is a 36-kDa nucleoside hydrolase (NH36). In this study, we tested the immune response and protection induced by the purified FML, the recombinant NH36 (rNH36), and NH36 DNA vaccines against the agents of visceral (L. chagasi) and cutaneous (L. mexicana) leishmaniasis in BALB/c mice. Mice developed weak humoral response to the vaccines alone, except for those immunized with FML. However, all three vaccine groups presented elevated immunoglobulin G (IgG), IgG1, and IgG2a levels after infection withL. chagasi, whereas no differences were observed between vaccine and control groups after infection withL. mexicana. A strong intradermal reaction toL. donovaniandL. mexicanaantigens was observed in mice immunized with rNH36 or FML, whereas mice immunized with NH36 DNA only reacted againstL. donovaniantigens. Experimental infection of immunized mice demonstrated that FML and rNH36 induced significant protection againstL. chagasiinfection with reductions in parasite loads of 79%. FML also conferred partial protection againstL. mexicanainfection. The best protection was observed in mice immunized with the VR1012-NH36 DNA vaccine, which induced an 88% reduction inL. chagasiparasite load and a 65% reduction inL. mexicanalesion size. Fluorescence-activated cell sorting analysis indicated the DNA vaccine induced a two- to fivefold increase in gamma interferon-producing CD4+T cells, indicating a Th1-type immune response. Our results showed that the NH36 DNA vaccine induced a strong immunoprotection against visceral and cutaneous leishmaniasis, suggesting that this DNA vaccine represents a very good candidate for use against severalLeishmaniaspecies.Keywords
This publication has 55 references indexed in Scilit:
- Intracutaneous DNA Vaccination with the E8 Gene of Cottontail Rabbit Papillomavirus Induces Protective Immunity against Virus Challenge in RabbitsJournal of Virology, 2002
- Leishmania donovanip36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral LeishmaniasisInfection and Immunity, 2001
- A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania majorVaccine, 2001
- Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovaniVaccine, 2001
- A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S o Gon alo do Amaranto, RN)Vaccine, 2000
- The Strange Case of Leishmania chagasiParasitology Today, 2000
- Characterization of the memory/activated T cells that mediate the long‐lived host response against tuberculosis after bacillus Calmette–Guérin or DNA vaccinationImmunology, 1999
- Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovaniVaccine, 1999
- Inosine−Uridine Nucleoside Hydrolase from Crithidia fasciculata. Genetic Characterization, Crystallization, and Identification of Histidine 241 as a Catalytic Site Residue,Biochemistry, 1996
- Visceral Leishmaniasis Due to a Leishmania Variant That Shares Kinetoplast DNA Sequences with Leishmania braziliensis and Leishmania mexicana in a Patient Infected with Human Immunodeficiency Virus: Identification of the Leishmania Species with Use of the Polymerase Chain ReactionClinical Infectious Diseases, 1995